Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

Painful wait for women as unfounded claims delay payout

It could be another 12 months before a $405 million settlement for pelvic mesh injuries is fully paid out but the tidal wave of pain goes on for those hurt.

AAP

Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity

Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch.

MarketBeat

3 Market-Beating Dividend Kings for Generations of Income

Three top-performing Dividend Kings combine decades of dividend growth with strong share-price gains and bullish analyst ratings.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

TSMC Could Swing $150 Billion as Options Market Prices Big Moves for This Week’s Earnings

Earnings season kicks into high gear next week, with a slate of heavyweight companies set to report quarterly results between July 12 and July 18. As investors look for fresh insight into corporate earnings, guidance and the broader economic backdrop, options traders are already betting on how sharply these stocks…

Benzinga

‘This was a righteous case. A holy war’: the lawyer who took on Meta and Google – and won

When Mark Lanier and his young client Kaley faced the tech giants in an LA courtroom earlier this year, it seemed a bigger battle than David v Goliath. But they scored a landmark victory, proving that the social media giants had created ‘addiction machines’ that harmed mental health. How did…

The Guardian - UK

PepsiCo and more: Jim Cramer says market rotation is creating buying chances, picks 4 stocks

Jim Cramer said the latest market rotation has created attractive buying opportunities as institutional selling dragged down quality stocks. He highlighted PepsiCo, Starbucks, Constellation Brands, TJX Companies and Johnson & Johnson as potential picks despite recent market weakness.

The Economic Times

MAGA Alliance Fractures Over Toxic Talc As Donald Trump Allegedly Abandons Asbestos Checks To Please Billionaire Execs

The FDA's withdrawal of a talc testing rule has intensified tensions between Trump's MAGA base and Kennedy's health movement, highlighting corporate influence and internal discord.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

These 3 Dividend Stocks Could Boost Your Income This July

Realty Income, Johnson & Johnson, and Chevron offer yields ranging from 2.2% to 5.1% in July 2026, supported by analyst buy ratings and institutional accumulation.

MarketBeat

Johnson & Johnson Earnings Preview: What to Expect

Johnson & Johnson is scheduled to report its second-quarter results next month, and analysts expect a single-digit earnings rise.

Barchart

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

The Economic Times

Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use

Legend Biotech (NASDAQ:LEGN) used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma developed, manufactured and co-promoted with Johnson & Johnson. Chief Executive Of

MarketBeat

3 Dividend Kings to Buy Now to Replace the Social Security Income You're About to Lose

The Congressional Budget Office (CBO) released a report this year containing one number that should change how every American near retirement thinks about income. Here's 3 dividend stocks to replace that lost income.

Barchart

Igor Taldenko: "A Website Outage Today Is an Event That Affects People's Lives"

An engineer with over 12 years of experience working with high-load systems explains why a website outage is no longer just a bug — it's an event capable of derailing transactions, delaying payments, and even impacting people's health — and how to build architecture that minimizes these risks.

inkl

Is Johnson & Johnson Stock Outperforming the Dow?

Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

The Texas Tribune

Ken Paxton wanted to limit forum shopping. Now lawyers say he’s improperly seeking favorable courts.

ProPublica and The Texas Tribune have identified at least 30 lawsuits filed by the attorney general over the past nine years that have a tenuous connection to the counties in which they were filed.

The Economic Times

From ₹5,000 salary to ₹48 crore turnover: Meet Nayana Vaidya, a pharma saleswoman, who built a healthcare distribution company from scratch

Nayana Vaidya built Om Sai Surgicals from a modest beginning. Her company achieved a turnover of nearly ₹48 crore. Vaidya finds satisfaction in the work itself, not just the financial success. Her journey highlights patience and steady growth in the healthcare distribution sector. She earned her first crore around 2010.

MarketBeat

Stereotaxis Q1 Earnings Call Highlights

Stereotaxis (NYSEAMERICAN:STXS) said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system. Chairman and CEO David Fischel told investors that t

MarketBeat

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment and international markets expanded. Chief Executive Officer Ying Huang said the company beg

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3 Dividend Aristocrats With Soaring Profits That Wall Street Says to Buy Now

3 Dividend Aristocrats with strong profit growth, safe payout ratios, decades of raises, and Buy-rated Wall Street support.

The Conversation

Foreign aid’s hidden benefit: Recipients are more likely to pay the generosity forward

Foreign aid may not improve how recipients view donor countries – but it can set off a chain of goodwill that spreads far beyond the original act of giving.

International Business Times

Johnson & Johnson Plans to Sell Prescription Drugs to TrumpRx in Cost-Reduction Push

Johnson & Johnson will sell diabetes and blood thinner drugs on TrumpRx as part of a U.S. push to reduce prescription medication costs.

MarketBeat

3 Giant Dividend Stocks Raising Payouts With Yields Up to 4%

Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025.

Kiplinger

5 Stocks to Buy With Your 2026 Tax Refund

Wondering what to do with your tax refund? Investing in high-quality stocks is one option and these five picks are a good place to start.

MarketBeat

Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results

JNJ stock is on track to rally higher after better-than-expected results. Cash flow and growth say this dividend story is reliable.

Barchart

Is This Dividend King With a 63-Year Dividend Streak A Buy Before April 14?

This Dividend King offers a rare mix of safety and upside heading into earnings.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations